1Higdon JV & Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43, 89–143.
2Pharn-Huy LAN, He H & Phamhuy C (2008) Green tea and health: an overview. J Food Agric Environ 6, 6–13.
3Miyazawa T (2000) Absorption, metabolism and antioxidative effects of tea catechin in humans. Biofactors 13, 55–59.
4Manach C, Williamson G, Morand C, et al. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81, 230S–242S.
5Lee MJ, Maliakal P, Chen LS, et al. (2002) Pharmacokinetics of tea catechins after ingestion of green tea and ( − )-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11, 1025–1032.
6Warden BA, Smith LS, Beecher GR, et al. (2001) Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 131, 1731–1737.
7Li C, Lee MJ, Sheng SQ, et al. (2000) Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem Res Toxicol 13, 177–184.
8Lu H, Meng XF & Yang CS (2003) Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by ( − )-epigallocatechin gallate. Drug Metab Dispos 31, 572–579.
9Kuhnle G, Spencer JP, Schroeter H, et al. (2000) Epicatechin and catechin are O-methylated and glucuronidated in the small intestine. Biochem Biophys Res Commun 277, 507–512.
10Feng WY (2006) Metabolism of green tea catechins: an overview. Curr Drug Metab 7, 755–809.
11Lu H, Meng XF, Li C, et al. (2003) Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 31, 452–461.
12Lambert JD, Rice JE, Hong J, et al. (2005) Synthesis and biological activity of the tea catechin metabolites, M4 and M6 and their methoxy-derivatives. Bioorg Med Chem Lett 15, 873–876.
13Nanjo F, Mori M, Goto K, et al. (1999) Radical scavenging activity of tea catechins and their related compounds. Biosci Biotechnol Biochem 63, 1621–1623.
14Koga T & Meydani M (2001) Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am J Clin Nutr 73, 941–948.
15Cybulsky MI & Gimbrone MA Jr (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251, 788–791.
16Rohde LE, Lee RT, Rivero J, et al. (1998) Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 18, 1765–1770.
17Dong ZM, Chapman SM, Brown AA, et al. (1998) The combined role of P- and E-selectins in atherosclerosis. J Clin Invest 102, 145–152.
18Collins RG, Velji R, Guevara NV, et al. (2000) P-selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 191, 189–194.
19Schachinger V, Britten MB & Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899–1906.
20Anderson TJ, Uehata A, Gerhard MD, et al. (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26, 1235–1241.
21Heitzer T, Schlinzig T, Krohn K, et al. (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104, 2673–2678.
22Halcox JPJ, Schenke WH, Zalos G, et al. (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653–658.
23Landmesser U, Hornig B & Drexler H (2004) Endothelial function – a critical determinant in atherosclerosis? Circulation 109, 27–33.
24Chan NN, Colhoun HM & Vallance P (2001) Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol 38, 1814–1820.
25Imai K & Nakachi K (1995) Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 310, 693–696.
26Sano J, Inami S, Seimiya K, et al. (2004) Effects of green tea intake on the development of coronary artery disease. Circ J 68, 665–670.
27Sasazuki S, Kodama H, Yoshimasu K, et al. (2000) Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol 10, 401–408.
28Hirano R, Momiyama Y, Takahashi R, et al. (2002) Comparison of green tea intake in Japanese patients with and without angiographic coronary artery disease. Am J Cardiol 90, 1150–1153.
29Kuriyama S, Shimazu T, Ohmori K, et al. (2006) Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 296, 1255–1265.
30Nakachi K, Matsuyama S, Miyake S, et al. (2000) Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 13, 49–54.
31Widlansky ME, Hamburg NM, Anter E, et al. (2007) Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 26, 95–102.
32Ryu OH, Lee J, Lee KW, et al. (2006) Effects of green tea consumption on inflammation, insulin resistance and pulse wave velocity in type 2 diabetes patients. Diabetes Res Clin Pract 71, 356–358.
33Kim W, Jeong MH, Cho SH, et al. (2006) Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 70, 1052–1057.
34Tinahones Madueño FJ, Rubio MA, Garrido Sánchez L, et al. (2007) Green tea reduces LDL oxidability and improves vascular function. Atheroscler Suppl 8, 166.
35Lee W, Min WK, Chun S, et al. (2005) Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem 38, 84–87.
36Jochmann N, Lorenz M, Krosigk AV, et al. (2008) The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br J Nutr 99, 863–868.
37Nagaya N, Yamamoto H, Uematsu M, et al. (2004) Green tea reverses endothelial dysfunction in healthy smokers. Heart 90, 1485–1486.
38Alexopoulos N, Vlachopoulos C, Aznaouridis K, et al. (2008) The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 15, 300–305.
39Antonello M, Montemurro D, Bolognesi M, et al. (2007) Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens 20, 1321–1328.
40Potenza MA, Marasciulo FL, Tarquinio M, et al. (2007) EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 292, E1378–E1387.
41Chyu KY, Babbidge SM, Zhao X, et al. (2004) Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 109, 2448–2453.
42Miura Y, Chiba T, Tomita I, et al. (2001) Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 131, 27–32.
43Song L, Koo MWL, Lau CP, et al. (2008) Effects of green tea on lipids, blood pressure and vasorelaxation in rats with hypercholesterolaemia-induced hypertension. Int J Cardiol 125, Suppl. 1, S64.
44Sanae F, Miyaichi Y, Kizu H, et al. (2002) Effects of catechins on vascular tone in rat thoracic aorta with endothelium. Life Sci 71, 2553–2562.
45Ajay M, Gilani AU & Mustafa MR (2003) Effects of flavonoids on vascular smooth muscle of the isolated rat thoracic aorta. Life Sci 74, 603–612.
46Fitzpatrick DF, Hirschfield SL, Ricci T, et al. (1995) Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol 26, 90–95.
47Lim DY, Lee ES, Park HG, et al. (2003) Comparison of green tea extract and epigallocatechin gallate on blood pressure and contractile responses of vascular smooth muscle of rats. Arch Pharm Res 26, 214–223.
48Lorenz M, Wessler S, Follmann E, et al. (2004) A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem 279, 6190–6195.
49Shen JZ, Zheng XF, Wei EQ, et al. (2003) Green tea catechins evoke a phasic contraction in rat aorta via H2O2-mediated multiple-signalling pathways. Clin Exp Pharmacol Physiol 30, 88–95.
50Alvarez E, Campos-Toimil M, Justiniano-Basaran H, et al. (2006) Study of the mechanisms involved in the vasorelaxation induced by ( − )-epigallocatechin-3-gallate in rat aorta. Br J Pharmacol 147, 269–280.
51Pfeffer U, Ferrari N, Dell'Eva R, et al. (2005) Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat Res 591, 198–211.
52Fang M, Chen D & Yang CS (2007) Dietary polyphenols may affect DNA methylation. J Nutr 137, Suppl. 1, 223S–228S.
53Schewe T, Steffen Y & Sies H (2008) How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys 476, 102–106.
54Steffen Y, Gruber C, Schewe T, et al. (2008) Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 469, 209–219.
55Mizugaki M, Ishizawa F, Yamazaki T, et al. (2000) Epigallocatechin gallate increase the prostacyclin production of bovine aortic endothelial cells. Prostaglandins Other Lipid Mediat 62, 157–164.
56Yamakuchi M, Bao C, Ferlito M, et al. (2008) Epigallocatechin gallate inhibits endothelial exocytosis. Biol Chem 389, 935–941.
57Ludwig A, Lorenz M, Grimbo N, et al. (2004) The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 316, 659–665.
58Boger RH (2003) Asymmetric dimethylarginine (ADMA) modulates endothelial function – therapeutic implications. Vasc Med 8, 149–151.
59Jiang JL, Jiang DJ, Tang YH, et al. (2004) Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 25, 893–901.
60Tang WJ, Hu CP, Chen MF, et al. (2006) Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can J Physiol Pharmacol 84, 163–171.
61Actis-Goretta L, Ottaviani JI & Fraga CG (2006) Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. J Agric Food Chem 54, 229–234.
62Paquay JB, Haenen GR, Stender G, et al. (2000) Protection against nitric oxide toxicity by tea. J Agric Food Chem 48, 5768–5772.
63Chow HHS, Cai Y, Alberts DS, et al. (2001) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10, 53–58.
64Yang CS, Chen LS, Lee MJ, et al. (1998) Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7, 351–354.
65Ruston D, Hoare J, Henderson L, et al. (2004) National Diet and Nutrition Survey: Adults Aged 19 to 64 Years. Volume 4: Nutritional Status (Anthropometry and Blood Analytes), Blood Pressure and Physical Activity. London: FSA.
66Duffy SJ, Keaney JF Jr, Holbrook M, et al. (2001) Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104, 151–156.
67Hodgson JM, Puddey IB, Croft KD, et al. (2000) Acute effects of ingestion of black and green tea on lipoprotein oxidation. Am J Clin Nutr 71, 1103–1107.
68Lotito SB & Frei B (2006) Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 41, 1727–1746.
69Da Silva EL, Piskula M & Terao J (1998) Enhancement of antioxidative ability of rat plasma by oral administration of ( − )-epicatechin. Free Radic Biol Med 24, 1209–1216.
70Benzie IF, Szeto YT, Strain JJ, et al. (1999) Consumption of green tea causes rapid increase in plasma antioxidant power in humans. Nutr Cancer 34, 83–87.
71Leenen R, Roodenburg AJ, Tijburg LB, et al. (2000) A single dose of tea with or without milk increases plasma antioxidant activity in humans. Eur J Clin Nutr 54, 87–92.
72Erba D, Riso P, Bordoni A, et al. (2005) Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. J Nutr Biochem 16, 144–149.
73Scalbert A & Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130, Suppl. 8S, 2073S–2085S.
74Kim JA, Formoso G, Li Y, et al. (2007) Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem 282, 13736–13745.
75Wu CC, Hsu MC, Hsieh CW, et al. (2006) Upregulation of heme oxygenase-1 by epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci 78, 2889–2897.
76Shenoy C (2000) Hypoglycemic activity of bio-tea in mice. Indian J Exp Biol 38, 278–279.
77Renno WM, Abdeen S, Alkhalaf M, et al. (2008) Effect of green tea on kidney tubules of diabetic rats. Br J Nutr 100, 652–659.
78Waltner-Law ME, Wang XL, Law BK, et al. (2002) Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem 277, 34933–34940.
79Anderson RA & Polansky MM (2002) Tea enhances insulin activity. J Agric Food Chem 50, 7182–7186.
80Wu LY, Juan CC, Ho LT, et al. (2004) Effect of green tea supplementation on insulin sensitivity in Sprague–Dawley rats. J Agric Food Chem 52, 643–648.
81Venables MC, Hulston CJ, Cox HR, et al. (2008) Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr 87, 778–784.
82Ramesh E, Elanchezhian R, Sakthivel M, et al. (2008) Epigallocatechin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet. Fundam Clin Pharmacol 22, 275–284.
83Yang TT & Koo MW (1997) Hypocholesterolemic effects of Chinese tea. Pharmacol Res 35, 505–512.
84Kono S, Shinchi K, Wakabayashi K, et al. (1996) Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. J Epidemiol 6, 128–133.
85Tokunaga S, White IR, Frost C, et al. (2002) Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol 12, 157–165.
86Koo SI & Noh SK (2007) Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J Nutr Biochem 18, 179–183.
87Yang TTC & Koo MWL (2000) Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. Life Sci 66, 411–423.
88Lee MS, Park JY, Freake H, et al. (2008) Green tea catechin enhances cholesterol 7α-hydroxylase gene expression in HepG2 cells. Br J Nutr 99, 1182–1185.
89Bu-Abbas A, Clifford MN, Ioannides C, et al. (1995) Stimulation of rat hepatic UDP-glucuronosyl transferase activity following treatment with green tea. Food Chem Toxicol 33, 27–30.
90Khokhar S & Magnusdottir SG (2002) Total phenol, catechin, and caffeine contents of teas commonly consumed in the United Kingdom. J Agric Food Chem 50, 565–570.
91Green RJ, Murphy AS, Schulz B, et al. (2007) Common tea formulations modulate in vitro digestive recovery of green tea catechins. Mol Nutr Food Res 51, 1152–1162.
92Chow HHS, Hakim IA, Vining DR, et al. (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11, 4627–4633.
93Schramm DD, Karim M, Schrader HR, et al. (2003) Food effects on the absorption and pharmacokinetics of cocoa flavanols. Life Sci 73, 857–869.
94Dawling S, Roodi N, Mernaugh RL, et al. (2001) Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 61, 6716–6722.
95Lampe JW (2007) Diet, genetic polymorphisms, detoxification, and health risks. Altern Ther Health Med 13, S108–S111.
96Nagar S, Zalatoris JJ & Blanchard RL (2004) Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14, 487–499.
97Sai K, Saito Y, Itoda M, et al. (2008) Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet 23, 139–147.
98Gawande S, Kale A & Kotwal S (2008) Effect of nutrient mixture and black grapes on the pharmacokinetics of orally administered ( − )epigallocatechin-3-gallate from green tea extract: a human study. Phytother Res 22, 802–808.
99Setchell KD, Brown NM & Lydeking-Olsen E (2002) The clinical importance of the metabolite equol – a clue to the effectiveness of soy and its isoflavones. J Nutr 132, 3577–3584.
100Del Rio D, Stewart AJ, Mullen W, et al. (2004) HPLC-MSn analysis of phenolic compounds and purine alkaloids in green and black tea. J Agric Food Chem 52, 2807–2815.